Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Jun;23(6):677–681. doi: 10.1111/j.1365-2125.1987.tb03101.x

Oral nafazatrom in man: effect on inhaled antigen challenge.

R W Fuller, N Maltby, R Richmond, C T Dollery, G W Taylor, W Ritter, E Philipp
PMCID: PMC1386161  PMID: 3038156

Abstract

The effect of oral nafazatrom (Bay g6575, 2 X 3 g) or placebo on inhaled antigen challenge was assessed in a double-blind study. In four subjects antigen challenge resulted in an immediate fall of 93.2 +/- 3.36% in airflow at 40% of vital capacity (Vp40) and a 45.85 +/- 4.95% reduction in forced partial expiratory volume at one second (FEV1). Neither nafazatrom nor placebo had any effect on baseline lung function or that after challenge. Leukotriene B4 was generated by ex vivo stimulus of blood with ionophore A23187, and quantified by high performance liquid chromatography (h.p.l.c.)-radioimmunoassay. No inhibition of LTB4 formation occurred ex vivo following oral nafazatrom, although addition of 10(-5) M nafazatrom to blood in vitro significantly inhibited LTB4 release. Peak plasma nafazatrom levels during the study ranged from 3.3 X 10(-7) M to 1.47 X 10(-6) M which are below the concentration (10(-5) M) at which significant 5-lipoxygenase inhibition occurs in vitro. Oral nafazatrom is ineffective as a 5-lipoxygenase inhibitor in man, probably because of poor bioavailability after administration.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes P. J., Gribbin H. R., Osmanliev D., Pride N. B. Partial flow-volume curves to measure bronchodilator dos-response curves in normal humans. J Appl Physiol Respir Environ Exerc Physiol. 1981 Jun;50(6):1193–1197. doi: 10.1152/jappl.1981.50.6.1193. [DOI] [PubMed] [Google Scholar]
  2. Blackwell G. J., Flower R. J. Inhibition of phospholipase. Br Med Bull. 1983 Jul;39(3):260–264. doi: 10.1093/oxfordjournals.bmb.a071830. [DOI] [PubMed] [Google Scholar]
  3. Dahlén S. E., Hedqvist P., Hammarström S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980 Dec 4;288(5790):484–486. doi: 10.1038/288484a0. [DOI] [PubMed] [Google Scholar]
  4. Deckmyn H., Van Houtte E., Verstraete M., Vermylen J. Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom. Biochem Pharmacol. 1983 Sep 15;32(18):2757–2762. doi: 10.1016/0006-2952(83)90088-6. [DOI] [PubMed] [Google Scholar]
  5. Fairfax A. J., Hanson J. M., Morley J. The late reaction following bronchial provocation with house dust mite allergen. Dependence on arachidonic acid metabolism. Clin Exp Immunol. 1983 May;52(2):393–398. [PMC free article] [PubMed] [Google Scholar]
  6. Fuller R. W., Dixon C. M., Dollery C. T., Barnes P. J. Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine. Am Rev Respir Dis. 1986 Feb;133(2):252–254. doi: 10.1164/arrd.1986.133.2.252. [DOI] [PubMed] [Google Scholar]
  7. Lewis R. A., Austen K. F. Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature. 1981 Sep 10;293(5828):103–108. doi: 10.1038/293103a0. [DOI] [PubMed] [Google Scholar]
  8. Marnett L. J., Siedlik P. H., Ochs R. C., Pagels W. R., Das M., Honn K. V., Warnock R. H., Tainer B. E., Eling T. E. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. Mol Pharmacol. 1984 Sep;26(2):328–335. [PubMed] [Google Scholar]
  9. Ritter W. Determination of nafazatrom in body fluids by high-performance thin-layer chromatography with post-chromatographic derivatization. J Chromatogr. 1984 May 4;290:97–105. doi: 10.1016/s0021-9673(01)93564-2. [DOI] [PubMed] [Google Scholar]
  10. Seuter F., Busse W. D., Meng K., Hoffmeister F., Möller E., Horstmann H. The antithrombotic activity of BAY g 6575. Arzneimittelforschung. 1979;29(1):54–59. [PubMed] [Google Scholar]
  11. Shephard E. G., Malan L., Macfarlane C. M., Mouton W., Joubert J. R. Lung function and plasma levels of thromboxane B2, 6-ketoprostaglandin F1 alpha and beta-thromboglobulin in antigen-induced asthma before and after indomethacin pretreatment. Br J Clin Pharmacol. 1985 Apr;19(4):459–470. doi: 10.1111/j.1365-2125.1985.tb02671.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Strasser T., Fischer S., Weber P. C. Inhibition of leukotriene B4 formation in human neutrophils after oral nafazatrom (Bay g 6575). Biochem Pharmacol. 1985 Jun 1;34(11):1891–1894. doi: 10.1016/0006-2952(85)90304-1. [DOI] [PubMed] [Google Scholar]
  13. Wong P. Y., Chao P. H., McGiff J. C. Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase. J Pharmacol Exp Ther. 1982 Dec;223(3):757–760. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES